

Supplemental Table 1. Causes of death

	MAC	RIC
Number of patients	525	89
Cause of death		
Primary disease	155 (30)	26 (29)
Graft failure	3 (<1)	2 (2)
GVHD	151 (29)	26 (29)
Infection	77 (15)	10 (11)
IPn/ARDS	9 (2)	1 (1)
Organ failure	43 (8)	3 (3)
Organ toxicity	1 (<1)	0
Secondary malignancy	4 (<1)	0
Vascular	64 (12)	18 (20)
Unknown	18 (3)	3 (3)

Abbreviations:

MAC, myeloablative conditioning; RIC, reduced intensity/non-myeloablative conditioning; GVHD, Graft-Versus-Host Disease; IPn, interstitial pneumonitis; ARDS, acute respiratory distress syndrome.

Supplemental Table 2. Multivariable analysis using Fine-Gray model for patients aged 18-60 years undergoing alloHCT using MAC versus RIC for CML, 2007-2014.

	HR	95% CI	P-value
Chronic GVHD			
MAC	1		
RIC	0.78	0.62-0.98	0.03
In vivo T cell depletion			
ATG alone	1		0.002
Alemtuzumab alone	0.56	0.29-1.05	0.07
No ATG/Alemtuzumab	1.27	1.05-1.53	0.01
Sex match			
MM	1		0.019
MF	0.87	0.72-1.05	0.14
FM	1.21	1.00-1.47	0.049
FF	1.08	0.89-1.32	0.44
Graft type			
BM	1		
PB	1.52	1.26-1.82	<0.0001
GVHD prophylaxis			
TAC	1		0.002
T-cell depletion/CD34	0.36	0.17-0.76	0.007
CSA	0.81	0.70-0.95	0.01
Other	0.68	0.46-1.00	0.05
Missing	0.43	0.09-2.13	0.30
Relapse			
Relapse ≤5 months			
MAC	1		
RIC	1.86	1.27-2.73	0.001
Relapse >5 months			
MAC	1		
RIC	0.60	0.35-1.03	0.06
Disease status			
CP1	1		<0.0001
AP	1.78	1.38-2.29	<0.0001
CP2+	1.71	1.28-2.28	0.0002
CP, NOS	1.35	0.41-4.44	0.62
Donor type			
HLA-identical sibling	1		0.0004
Well-matched unrelated	0.60	0.47-0.77	<0.0001
Partially-matched unrelated	0.57	0.38-0.85	0.006
Mismatched unrelated	0.62	0.16-2.47	0.50

URD-matching TBD	0.67	0.40-1.11	0.12
KPS			0.0001
≥90%	1		
<90%	1.65	1.30-2.09	<0.0001
Missing	1.08	0.69-1.67	0.74
Non-Relapse Mortality			
MAC	1		
RIC	0.92	0.70-1.22	0.57
Age			0.01
18-29	1		
30-39	1.31	0.91-1.86	0.14
40-49	1.52	1.09-2.11	0.01
50-59	1.73	1.24-2.42	0.001
Donor type			
HLA-identical sibling	1		
Well-matched unrelated	1.63	1.29-2.06	<0.0001
Partially-matched unrelated	1.96	1.40-2.74	<0.0001
Mismatched unrelated	3.01	1.23-7.36	0.01
URD-matching TBD	1.51	0.96-2.38	0.07
CMV match			0.03
+/+	1		
+/-	1.08	0.73-1.60	0.71
-/+	1.25	0.97-1.62	0.08
-/-	0.78	0.59-1.04	0.09
Missing	0.98	0.67-1.42	0.91
Graft type			
BM	1		
PB	1.27	0.99-1.64	0.06

Abbreviations:

CML, chronic myeloid leukemia; alloHCT, allogeneic hematopoietic cell transplantation; MAC, myeloablative conditioning; RIC, reduced intensity/non-myeloablative conditioning; CI, confidence interval; HCT, hematopoietic cell transplantation; HCT-CI, hematopoietic cell transplant-comorbidity index; CP1, chronic phase 1, AP, accelerated phase; CP2+, chronic phase ≥2; CP, NOS, chronic phase, not otherwise specified; KPS, Karnofsky Performance Score; TKI, tyrosine kinase inhibitor; BM, bone marrow; PB, peripheral blood; TBD, to be determined; HLA, human leukocyte antigen; URD, unrelated donor; CMV, cytomegalovirus; TBI, total body irradiation; Cy, cyclophosphamide; Flu, fludarabine; Bu, busulfan; Mel, melphalan; GVHD, Graft-Versus-Host Disease; TAC, tacrolimus; CSA, cyclosporine, ATG, Anti-thymocyte globulin; M, male; F, female.